- Home
- NKTX vs GECC Comparison
NKTX vs GECC Comparison
Compare NKTX & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- GECC
- Stock Information
- Founded
- NKTX 2015
- GECC 2016
- Country
- NKTX United States
- GECC United States
- Employees
- NKTX N/A
- GECC N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- GECC Finance: Consumer Services
- Sector
- NKTX Health Care
- GECC Finance
- Exchange
- NKTX Nasdaq
- GECC Nasdaq
- Market Cap
- NKTX 123.5M
- GECC 123.1M
- IPO Year
- NKTX 2020
- GECC N/A
- Fundamental
- Price
- NKTX $1.80
- GECC $10.94
- Analyst Decision
- NKTX Strong Buy
- GECC
- Analyst Count
- NKTX 6
- GECC 0
- Target Price
- NKTX $14.40
- GECC N/A
- AVG Volume (30 Days)
- NKTX 434.5K
- GECC 25.1K
- Earning Date
- NKTX 08-12-2025
- GECC 07-31-2025
- Dividend Yield
- NKTX N/A
- GECC 13.97%
- EPS Growth
- NKTX N/A
- GECC N/A
- EPS
- NKTX N/A
- GECC 0.42
- Revenue
- NKTX N/A
- GECC $42,909,000.00
- Revenue This Year
- NKTX N/A
- GECC $32.54
- Revenue Next Year
- NKTX N/A
- GECC N/A
- P/E Ratio
- NKTX N/A
- GECC $25.92
- Revenue Growth
- NKTX N/A
- GECC 18.13
- 52 Week Low
- NKTX $1.31
- GECC $8.87
- 52 Week High
- NKTX $8.23
- GECC $11.39
- Technical
- Relative Strength Index (RSI)
- NKTX 51.45
- GECC 58.09
- Support Level
- NKTX $1.68
- GECC $10.83
- Resistance Level
- NKTX $1.84
- GECC $10.60
- Average True Range (ATR)
- NKTX 0.08
- GECC 0.19
- MACD
- NKTX 0.01
- GECC 0.03
- Stochastic Oscillator
- NKTX 80.95
- GECC 100.00
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.